Citigroup Rates Sabra Health Care REIT (SBRA) hold
Analyst action brings a fresh look at Sabra Health Care REIT as shares hover near recent trading marks, a 1.61% downside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Citigroup rated Sabra Health Care REIT, Inc. ($SBRA) "hold" with a $19 price target on June 23, 2026.
Since the rating, $SBRA is up 4.7% after 1 week, up 18.3% after 1 month and up 5.4% to date (from the $18.35 close on Jun 23, 2026).
SBRA
Sabra Health Care REIT, Inc.
Key Points
- Citigroup lowered its rating on Sabra Health Care REIT, Inc. to a hold on June 23, 2026, and set a price target of $19.00.
- Citigroup's $19 price target implies 1.61% downside from Sabra Health Care REIT, Inc.'s ($SBRA) current $19.31 share price.
- The stock traded recently at $19.31, sitting very close to the new price target set by Citigroup analysts.
- Wall Street maintains an overall buy recommendation for the healthcare real estate trust, backed by a mean target price of $22.79.
Get $SBRA trade alerts by text
We text you when insiders, Congress or big funds trade $SBRA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Sabra Health Care REIT, Inc. alert may contain errors. Disclosures
Citigroup Adjusts Rating on Sabra Health Care REIT
Citigroup lowered its rating on Sabra Health Care REIT, Inc. [SBRA] to a hold on June 23, 2026. Analyst Nick Joseph set a price target of $19.00 for the healthcare real estate trust. This move brings fresh scrutiny to how the firm's valuation lines up with current market prices.
Citigroup vs. the S&P 500
Hypothetical returns from Citigroup's disclosed trades, not real profit or advice. How we model this.
Where Sabra Health Care REIT Shares Trade Right Now
Trading near $19.31 on a Tuesday, the stock sits right alongside Citigroup's new $19.00 target. Shares have moved within a 52-week band stretching from a low of $17.17 to a high of $22.77. The current price also tracks closely to the 200-day moving average of $19.93, while staying slightly below the 50-day moving average of $20.71.
$SBRA price target
Sabra Health Care REIT, Inc. daily closes and this analyst's $19 target. Not advice.
Recent Analyst Moves Across Wall Street
Other financial institutions have updated their views on the real estate investment trust over recent months. On October 13, 2026, UBS maintained a neutral rating with a $20.00 target, down from its prior target of $21.00. On the same day, Barclays kept an equal-weight rating while adjusting its target to $21.00 from $23.00. Earlier in the summer, Truist Securities kept a buy rating with a $24.00 target on July 22, 2026, and Citizens maintained a market outperform rating with a $25.00 target on the same date. Across 14 total opinions, the consensus recommendation stands at a buy with a mean price target of $22.79.
Financial Health and Recent Earnings
The company reported annual revenue of $863.8 million alongside a revenue growth rate of 25.3%. Profitability metrics show an earnings per share of $0.26, paired with a net margin of 7.58% and a return on equity of 2.39%. Market participants can look toward the company's next scheduled earnings report on November 4, 2026, for updated financial metrics.
Dividend Profile for Shareholders
The self-administered real estate investment trust pays an annual dividend of $1.20 per share, giving the stock a dividend yield of 6.04%. The dividend payout ratio stands at 4.62, distributing income to investors while the firm manages its healthcare real estate portfolio.
Inside Sabra Health Care REIT Operations
Based in Tustin, California, the company operates as a self-managed real estate investment trust that invests in facilities serving the healthcare industry across the United States and Canada. With a market capitalization near $5.08 billion, the firm focuses on senior housing, skilled nursing, and specialized medical properties.
What to Watch Next for Sabra Health Care REIT
Investors will keep an eye on upcoming analyst revisions and the company's November earnings release to gauge operational progress. Market conditions and healthcare sector trends will likely dictate how closely the stock tracks toward the broader Wall Street consensus target of $22.79 in the coming months.
Related Filing Alerts
Source: Citigroup's rating change on $SBRA (Jun 23, 2026). Written by software, not financial advice. How we make alerts